JMJD2C triggers the growth of multiple myeloma cells via activation of β‑catenin

Lv,Ming; Liu,Qicai

doi:10.3892/or.2021.7934

JMJD2C triggers the growth of multiple myeloma cells via activation of β‑catenin

Authors:
- Ming Lv
- Qicai Liu
View Affiliations

Affiliations: Department of Emergency Medicine, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277101, P.R. China, Department of Joint Surgery, Zaozhuang Municipal Hospital, Zaozhuang, Shandong 277101, P.R. China
Published online on: January 14, 2021 https://doi.org/10.3892/or.2021.7934
Pages: 1162-1170
Copyright: © Lv et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Emerging evidence has indicated that histone modification and its related regulators are involved in the progression of multiple myeloma (MM) cells. In the present study, the expression of Jumonji C domain‑containing 2 (JMJD2) was examined in both MM tissues and healthy controls. The roles of JMJD2C in the progression of MM were further investigated. The results revealed that the expression of JMJD2C, but not that of JMJD2A or JMJD2B, was increased in MM tissues compared with the healthy controls. The overexpression of JMJD2C significantly increased the in vitro growth of MM cells. The inhibitor of the β‑catenin signaling pathway significantly attenuated the JMJD2C‑induced growth of MM cells. Mechanistical analyses indicated that JMJD2C increased the transcription of β‑catenin in MM cells, which may be due to the fact that JMJD2C can directly bind with the promoter of β‑catenin. Furthermore, JMJD2C activated β‑catenin in MM cells via a GSK3β‑dependent manner, which was evidenced by the results demonstrating that the overexpression of GSK3β attenuated the JMJD2C‑induced decrease in the phosphorylation of β‑catenin. On the whole, the findings of the present study demonstrated that JMJD2C promotes the malignancy of MM via the activation of the β‑catenin pathway. These results suggested that JMJD2C may be a potential target for MM treatment.

View Figures

View References

1	Moreau P, San Miguel J, Sonneveld P, Mateos MV, Zamagni E, Avet-Loiseau H, Hajek R, Dimopoulos MA, Ludwig H, Einsele H, et al ESMO Guidelines Committee, : Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 28 (Suppl_4):iv52–iv61. 2017. View Article : Google Scholar : PubMed/NCBI
2	Merz AMA, Merz M, Hillengass J, Holstein SA and McCarthy P: The evolving role of maintenance therapy following autologous stem cell transplantation in multiple myeloma. Expert Rev Anticancer Ther. 19:889–898. 2019. View Article : Google Scholar : PubMed/NCBI
3	Gandolfi S, Vekstein C, Laubach JP, O'Brien A, Masone K, Munshi NC, Anderson KC and Richardson PG: The evolving role of transplantation in multiple myeloma: The need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 16:564–574. 2018.PubMed/NCBI
4	Robiou du Pont S, Cleynen A, Fontan C, Attal M, Munshi N, Corre J and Avet-Loiseau H: Genomics of Multiple Myeloma. J Clin Oncol. 35:963–967. 2017. View Article : Google Scholar : PubMed/NCBI
5	Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X and Anderson KC: Correction: Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 33:1058–1059. 2019. View Article : Google Scholar : PubMed/NCBI
6	Brioli A, Klaus M, Sayer H, Scholl S, Ernst T, Hilgendorf I, Scherag A, Yomade O, Schilling K, Hochhaus A, et al: The risk of infections in multiple myeloma before and after the advent of novel agents: A 12-year survey. Ann Hematol. 98:713–722. 2019. View Article : Google Scholar : PubMed/NCBI
7	Marino S, Petrusca DN and Roodman GD: Therapeutic targets in myeloma bone disease. Br J Pharmacol. Oct 24–2019.(Epub ahead of print). doi: 10.1111/bph.14889. PubMed/NCBI
8	Webb SL and Edwards CM: Novel therapeutic targets in myeloma bone disease. Br J Pharmacol. 171:3765–3776. 2014. View Article : Google Scholar : PubMed/NCBI
9	Barwick BG, Gupta VA, Vertino PM and Boise LH: Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 10:11212019. View Article : Google Scholar : PubMed/NCBI
10	Moreau P, Attal M and Facon T: Frontline therapy of multiple myeloma. Blood. 125:3076–3084. 2015. View Article : Google Scholar : PubMed/NCBI
11	Yaqub S, Ballester G and Ballester O: Frontline therapy for multiple myeloma: A concise review of the evidence based on randomized clinical trials. Cancer Invest. 31:529–537. 2013. View Article : Google Scholar : PubMed/NCBI
12	Greig SL: Panobinostat: A Review in Relapsed or Refractory Multiple Myeloma. Target Oncol. 11:107–114. 2016. View Article : Google Scholar : PubMed/NCBI
13	Hideshima T, Richardson PG and Anderson KC: Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol Cancer Ther. 10:2034–2042. 2011. View Article : Google Scholar : PubMed/NCBI
14	Harada T, Ohguchi H, Grondin Y, Kikuchi S, Sagawa M, Tai YT, Mazitschek R, Hideshima T and Anderson KC: HDAC3 regulates DNMT1 expression in multiple myeloma: Therapeutic implications. Leukemia. 31:2670–2677. 2017. View Article : Google Scholar : PubMed/NCBI
15	Pourhanifeh MH, Mahjoubin-Tehran M, Shafiee A, Hajighadimi S, Moradizarmehri S, Mirzaei H and Asemi Z: MicroRNAs and exosomes: Small molecules with big actions in multiple myeloma pathogenesis. IUBMB Life. 72:314–333. 2020. View Article : Google Scholar : PubMed/NCBI
16	Van Rechem C and Whetstine JR: Examining the impact of gene variants on histone lysine methylation. Biochim Biophys Acta. 1839:1463–1476. 2014. View Article : Google Scholar : PubMed/NCBI
17	Zhang X, Liu L, Yuan X, Wei Y and Wei X: JMJD3 in the regulation of human diseases. Protein Cell. 10:864–882. 2019. View Article : Google Scholar : PubMed/NCBI
18	Ayrapetov MK, Gursoy-Yuzugullu O, Xu C, Xu Y and Price BD: DNA double-strand breaks promote methylation of histone H3 on lysine 9 and transient formation of repressive chromatin. Proc Natl Acad Sci USA. 111:9169–9174. 2014. View Article : Google Scholar : PubMed/NCBI
19	Li N and Jiang D: Jumonji domain containing 2C promotes cell migration and invasion through modulating CUL4A expression in lung cancer. Biomed Pharmacother. 89:305–315. 2017. View Article : Google Scholar : PubMed/NCBI
20	Agger K, Miyagi S, Pedersen MT, Kooistra SM, Johansen JV and Helin K: Jmjd2/Kdm4 demethylases are required for expression of Il3ra and survival of acute myeloid leukemia cells. Genes Dev. 30:1278–1288. 2016. View Article : Google Scholar : PubMed/NCBI
21	Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI
22	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
23	Nilsson K, Bennich H, Johansson SG and Pontén J: Established immunoglobulin producing myeloma (IgE) and lymphoblastoid (IgG) cell lines from an IgE myeloma patient. Clin Exp Immunol. 7:477–489. 1970.PubMed/NCBI
24	Pellat-Deceunynk C, Amiot M, Bataille R, van Riet I, van Camp B, Omede P and Boccadoro M: Human myeloma cell lines as a tool for studying the biology of multiple myeloma: A reappraisal 18 years after. Blood 86: 4001, 1995. Published Erratum Blood. 131:1542018.PubMed/NCBI
25	Gazdar AF, Oie HK, Kirsch IR and Hollis GF: Establishment and characterization of a human plasma cell myeloma culture having a rearranged cellular myc proto-oncogene. Blood. 67:1542–1549. 1986. View Article : Google Scholar : PubMed/NCBI
26	Kanasugi J, Hanamura I, Ota A, Karnan S, Lam VQ, Mizuno S, Wahiduzzaman M, Rahman ML, Hyodo T, Konishi H, et al: Biallelic loss of FAM46C triggers tumor growth with concomitant activation of Akt signaling in multiple myeloma cells. Cancer Sci. 111:1663–1675. 2020. View Article : Google Scholar : PubMed/NCBI
27	Wahiduzzaman M, Ota A, Karnan S, Hanamura I, Mizuno S, Kanasugi J, Rahman ML, Hyodo T, Konishi H, Tsuzuki S, et al: Novel combined Ato-C treatment synergistically suppresses proliferation of Bcr-Abl-positive leukemic cells in vitro and in vivo. Cancer Lett. 433:117–130. 2018. View Article : Google Scholar : PubMed/NCBI
28	Soriano AA, de Cristofaro T, Di Palma T, Dotolo S, Gokulnath P, Izzo A, Calì G, Facchiano A and Zannini M: PAX8 expression in high-grade serous ovarian cancer positively regulates attachment to ECM via Integrin β3. Cancer Cell Int. 19:3032019. View Article : Google Scholar : PubMed/NCBI
29	Hui RC, Francis RE, Guest SK, Costa JR, Gomes AR, Myatt SS, Brosens JJ and Lam EW: Doxorubicin activates FOXO3a to induce the expression of multidrug resistance gene ABCB1 (MDR1) in K562 leukemic cells. Mol Cancer Ther. 7:670–678. 2008. View Article : Google Scholar : PubMed/NCBI
30	Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, et al: Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 33:2863–2869. 2015. View Article : Google Scholar : PubMed/NCBI
31	Szász AM, Lánczky A, Nagy Á, Förster S, Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B: Cross-validation of survival associated biomarkers in gastric cancer using transcriptomic data of 1,065 patients. Oncotarget. 7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
32	Abdel-Magid AF: Wnt/β-Catenin Signaling Pathway Inhibitors: A Promising Cancer Therapy. ACS Med Chem Lett. 5:956–957. 2014. View Article : Google Scholar : PubMed/NCBI
33	Daugherty RL and Gottardi CJ: Phospho-regulation of Beta-catenin adhesion and signaling functions. Physiology (Bethesda). 22:303–309. 2007.PubMed/NCBI
34	Liu G, Bollig-Fischer A, Kreike B, van de Vijver MJ, Abrams J, Ethier SP and Yang ZQ: Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene. 28:4491–4500. 2009. View Article : Google Scholar : PubMed/NCBI
35	Kahl P, Gullotti L, Heukamp LC, Wolf S, Friedrichs N, Vorreuther R, Solleder G, Bastian PJ, Ellinger J, Metzger E, et al: Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res. 66:11341–11347. 2006. View Article : Google Scholar : PubMed/NCBI
36	Ye Q, Holowatyj A, Wu J, Liu H, Zhang L, Suzuki T and Yang ZQ: Genetic alterations of KDM4 subfamily and therapeutic effect of novel demethylase inhibitor in breast cancer. Am J Cancer Res. 5:1519–1530. 2015.PubMed/NCBI
37	Nusse R and Clevers H: Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities. Cell. 169:985–999. 2017. View Article : Google Scholar : PubMed/NCBI
38	van Andel H, Kocemba KA, Spaargaren M and Pals ST: Aberrant Wnt signaling in multiple myeloma: Molecular mechanisms and targeting options. Leukemia. 33:1063–1075. 2019. View Article : Google Scholar : PubMed/NCBI
39	Wang H, Gong Y, Liang L, Xiao L, Yi H, Ye M, Roy M, Xia J, Zhou W, Yang C, et al: Lycorine targets multiple myeloma stem cell-like cells by inhibition of Wnt/β-catenin pathway. Br J Haematol. 189:1151–1164. 2020. View Article : Google Scholar : PubMed/NCBI
40	Su N, Wang P and Li Y: Role of Wnt/β-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. Oncol Lett. 12:4623–4629. 2016. View Article : Google Scholar : PubMed/NCBI
41	Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D and Schmidt-Wolf IG: Targeting the Wnt/beta-catenin pathway in multiple myeloma. Anticancer Res. 33:4719–4726. 2013.PubMed/NCBI
42	Yamamoto S, Tateishi K, Kudo Y, Yamamoto K, Isagawa T, Nagae G, Nakatsuka T, Asaoka Y, Ijichi H, Hirata Y, et al: Histone demethylase KDM4C regulates sphere formation by mediating the cross talk between Wnt and Notch pathways in colonic cancer cells. Carcinogenesis. 34:2380–2388. 2013. View Article : Google Scholar : PubMed/NCBI
43	Guo L, Guo YY, Li BY, Peng WQ and Tang QQ: Histone demethylase KDM5A is transactivated by the transcription factor C/EBPβ and promotes preadipocyte differentiation by inhibiting Wnt/β-catenin signaling. J Biol Chem. 294:9642–9654. 2019. View Article : Google Scholar : PubMed/NCBI